Market Overview

Medtronic Presents Positive Data from Symplicity HTN-1


Medtronic, Inc. (NYSE: MDT), announced today at the European Society of Cardiology (ESC) Congress the final three-year results from Symplicity HTN-1, the first and longest running clinical study investigating the safety and efficacy of renal denervation, which also have been accepted for publication in The Lancet. Eighty-eight (88) treatment-resistant hypertension patients were available for 36 month evaluations following treatment with the Symplicity(TM) renal denervation system. These 88 patients demonstrated sustained reductions in blood pressure year-over-year with an average reduction of -32/-14 mm Hg [p<0.01]. Of these 88 patients, approximately 50 percent achieved goal of a systolic blood pressure <140 mm Hg despite having a mean systolic blood pressure of 169.8 mm Hg pre-denervation. There were very few clinically significant late adverse events reported through three years of follow up. "We are pleased to find that we're seeing sustained and significant blood pressure reductions overall in all patients who reached the three year time point following their denervation procedure.  Achieving goal of

See full press release

Posted-In: News Guidance Contracts Management Stock Split Global


Related Articles (MDT)

View Comments and Join the Discussion!

Partner Center